Determining minimal clinically important differences in the North Star Ambulatory Assessment (NSAA) for patients with Duchenne muscular dystrophy

The North Star ambulatory assessment (NSAA) is a functional motor outcome measure in Duchenne muscular dystrophy (DMD), widely used in clinical trials and natural history studies, as well as in clinical practice. However, little has been reported on the minimal clinically important difference (MCID)...

Full description

Bibliographic Details
Main Authors: Vandana Ayyar Gupta, Jacqueline M. Pitchforth, Joana Domingos, Deborah Ridout, Mario Iodice, Catherine Rye, Mary Chesshyre, Amy Wolfe, Victoria Selby, Anna Mayhew, Elena S. Mazzone, Valeria Ricotti, Jean-Yves Hogrel, Erik H. Niks, Imelda de Groot, Laurent Servais, Volker Straub, Eugenio Mercuri, Adnan Y. Manzur, Francesco Muntoni
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2023-01-01
Series:PLoS ONE
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10132589/?tool=EBI
_version_ 1797836832355909632
author Vandana Ayyar Gupta
Jacqueline M. Pitchforth
Joana Domingos
Deborah Ridout
Mario Iodice
Catherine Rye
Mary Chesshyre
Amy Wolfe
Victoria Selby
Anna Mayhew
Elena S. Mazzone
Valeria Ricotti
Jean-Yves Hogrel
Erik H. Niks
Imelda de Groot
Laurent Servais
Volker Straub
Eugenio Mercuri
Adnan Y. Manzur
Francesco Muntoni
author_facet Vandana Ayyar Gupta
Jacqueline M. Pitchforth
Joana Domingos
Deborah Ridout
Mario Iodice
Catherine Rye
Mary Chesshyre
Amy Wolfe
Victoria Selby
Anna Mayhew
Elena S. Mazzone
Valeria Ricotti
Jean-Yves Hogrel
Erik H. Niks
Imelda de Groot
Laurent Servais
Volker Straub
Eugenio Mercuri
Adnan Y. Manzur
Francesco Muntoni
author_sort Vandana Ayyar Gupta
collection DOAJ
description The North Star ambulatory assessment (NSAA) is a functional motor outcome measure in Duchenne muscular dystrophy (DMD), widely used in clinical trials and natural history studies, as well as in clinical practice. However, little has been reported on the minimal clinically important difference (MCID) of the NSAA. The lack of established MCID estimates for NSAA presents challenges in interpreting the significance of the results of this outcome measure in clinical trials, natural history studies and clinical practice. Combining statistical approaches and patient perspectives, this study estimated MCID for NSAA using distribution-based estimates of 1/3 standard deviation (SD) and standard error of measurement (SEM), an anchor-based approach, with six-minute walk distance (6MWD) as the anchor, and evaluation of patient and parent perception using participant-tailored questionnaires. The MCID for NSAA in boys with DMD aged 7 to 10 years based on 1/3 SD ranged from 2.3–2.9 points, and that on SEM ranged from 2.9–3.5 points. Anchored on the 6MWD, the MCID for NSAA was estimated as 3.5 points. When the impact on functional abilities was considered using participant response questionnaires, patients and parent perceived a complete loss of function in a single item or deterioration of function in one to two items of the assessment as an important change. Our study examines MCID estimates for total NSAA scores using multiple approaches, including the impact of patient and parent perspective on within scale changes in items based on complete loss of function and deterioration of function, and provides new insight on evaluation of differences in these widely used outcome measure in DMD.
first_indexed 2024-04-09T15:15:16Z
format Article
id doaj.art-a350ca5f353944d0a6c92faad79a4f3f
institution Directory Open Access Journal
issn 1932-6203
language English
last_indexed 2024-04-09T15:15:16Z
publishDate 2023-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj.art-a350ca5f353944d0a6c92faad79a4f3f2023-04-30T05:31:20ZengPublic Library of Science (PLoS)PLoS ONE1932-62032023-01-01184Determining minimal clinically important differences in the North Star Ambulatory Assessment (NSAA) for patients with Duchenne muscular dystrophyVandana Ayyar GuptaJacqueline M. PitchforthJoana DomingosDeborah RidoutMario IodiceCatherine RyeMary ChesshyreAmy WolfeVictoria SelbyAnna MayhewElena S. MazzoneValeria RicottiJean-Yves HogrelErik H. NiksImelda de GrootLaurent ServaisVolker StraubEugenio MercuriAdnan Y. ManzurFrancesco MuntoniThe North Star ambulatory assessment (NSAA) is a functional motor outcome measure in Duchenne muscular dystrophy (DMD), widely used in clinical trials and natural history studies, as well as in clinical practice. However, little has been reported on the minimal clinically important difference (MCID) of the NSAA. The lack of established MCID estimates for NSAA presents challenges in interpreting the significance of the results of this outcome measure in clinical trials, natural history studies and clinical practice. Combining statistical approaches and patient perspectives, this study estimated MCID for NSAA using distribution-based estimates of 1/3 standard deviation (SD) and standard error of measurement (SEM), an anchor-based approach, with six-minute walk distance (6MWD) as the anchor, and evaluation of patient and parent perception using participant-tailored questionnaires. The MCID for NSAA in boys with DMD aged 7 to 10 years based on 1/3 SD ranged from 2.3–2.9 points, and that on SEM ranged from 2.9–3.5 points. Anchored on the 6MWD, the MCID for NSAA was estimated as 3.5 points. When the impact on functional abilities was considered using participant response questionnaires, patients and parent perceived a complete loss of function in a single item or deterioration of function in one to two items of the assessment as an important change. Our study examines MCID estimates for total NSAA scores using multiple approaches, including the impact of patient and parent perspective on within scale changes in items based on complete loss of function and deterioration of function, and provides new insight on evaluation of differences in these widely used outcome measure in DMD.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10132589/?tool=EBI
spellingShingle Vandana Ayyar Gupta
Jacqueline M. Pitchforth
Joana Domingos
Deborah Ridout
Mario Iodice
Catherine Rye
Mary Chesshyre
Amy Wolfe
Victoria Selby
Anna Mayhew
Elena S. Mazzone
Valeria Ricotti
Jean-Yves Hogrel
Erik H. Niks
Imelda de Groot
Laurent Servais
Volker Straub
Eugenio Mercuri
Adnan Y. Manzur
Francesco Muntoni
Determining minimal clinically important differences in the North Star Ambulatory Assessment (NSAA) for patients with Duchenne muscular dystrophy
PLoS ONE
title Determining minimal clinically important differences in the North Star Ambulatory Assessment (NSAA) for patients with Duchenne muscular dystrophy
title_full Determining minimal clinically important differences in the North Star Ambulatory Assessment (NSAA) for patients with Duchenne muscular dystrophy
title_fullStr Determining minimal clinically important differences in the North Star Ambulatory Assessment (NSAA) for patients with Duchenne muscular dystrophy
title_full_unstemmed Determining minimal clinically important differences in the North Star Ambulatory Assessment (NSAA) for patients with Duchenne muscular dystrophy
title_short Determining minimal clinically important differences in the North Star Ambulatory Assessment (NSAA) for patients with Duchenne muscular dystrophy
title_sort determining minimal clinically important differences in the north star ambulatory assessment nsaa for patients with duchenne muscular dystrophy
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10132589/?tool=EBI
work_keys_str_mv AT vandanaayyargupta determiningminimalclinicallyimportantdifferencesinthenorthstarambulatoryassessmentnsaaforpatientswithduchennemusculardystrophy
AT jacquelinempitchforth determiningminimalclinicallyimportantdifferencesinthenorthstarambulatoryassessmentnsaaforpatientswithduchennemusculardystrophy
AT joanadomingos determiningminimalclinicallyimportantdifferencesinthenorthstarambulatoryassessmentnsaaforpatientswithduchennemusculardystrophy
AT deborahridout determiningminimalclinicallyimportantdifferencesinthenorthstarambulatoryassessmentnsaaforpatientswithduchennemusculardystrophy
AT marioiodice determiningminimalclinicallyimportantdifferencesinthenorthstarambulatoryassessmentnsaaforpatientswithduchennemusculardystrophy
AT catherinerye determiningminimalclinicallyimportantdifferencesinthenorthstarambulatoryassessmentnsaaforpatientswithduchennemusculardystrophy
AT marychesshyre determiningminimalclinicallyimportantdifferencesinthenorthstarambulatoryassessmentnsaaforpatientswithduchennemusculardystrophy
AT amywolfe determiningminimalclinicallyimportantdifferencesinthenorthstarambulatoryassessmentnsaaforpatientswithduchennemusculardystrophy
AT victoriaselby determiningminimalclinicallyimportantdifferencesinthenorthstarambulatoryassessmentnsaaforpatientswithduchennemusculardystrophy
AT annamayhew determiningminimalclinicallyimportantdifferencesinthenorthstarambulatoryassessmentnsaaforpatientswithduchennemusculardystrophy
AT elenasmazzone determiningminimalclinicallyimportantdifferencesinthenorthstarambulatoryassessmentnsaaforpatientswithduchennemusculardystrophy
AT valeriaricotti determiningminimalclinicallyimportantdifferencesinthenorthstarambulatoryassessmentnsaaforpatientswithduchennemusculardystrophy
AT jeanyveshogrel determiningminimalclinicallyimportantdifferencesinthenorthstarambulatoryassessmentnsaaforpatientswithduchennemusculardystrophy
AT erikhniks determiningminimalclinicallyimportantdifferencesinthenorthstarambulatoryassessmentnsaaforpatientswithduchennemusculardystrophy
AT imeldadegroot determiningminimalclinicallyimportantdifferencesinthenorthstarambulatoryassessmentnsaaforpatientswithduchennemusculardystrophy
AT laurentservais determiningminimalclinicallyimportantdifferencesinthenorthstarambulatoryassessmentnsaaforpatientswithduchennemusculardystrophy
AT volkerstraub determiningminimalclinicallyimportantdifferencesinthenorthstarambulatoryassessmentnsaaforpatientswithduchennemusculardystrophy
AT eugeniomercuri determiningminimalclinicallyimportantdifferencesinthenorthstarambulatoryassessmentnsaaforpatientswithduchennemusculardystrophy
AT adnanymanzur determiningminimalclinicallyimportantdifferencesinthenorthstarambulatoryassessmentnsaaforpatientswithduchennemusculardystrophy
AT francescomuntoni determiningminimalclinicallyimportantdifferencesinthenorthstarambulatoryassessmentnsaaforpatientswithduchennemusculardystrophy